Accumark Labs: Are They Legit?
What One Verified BPC-157 COA Actually Shows

Accumark Labs has a real public business footprint, publishes laboratory contact information, and operates a live AccuVerify portal backed by its laboratory information system. The Omni Peptides BPC-157 record we checked resolves on that portal with matching client, lot, dates and results. That materially strengthens confidence that the certificate corresponds to an Accumark-issued record.

But “the lab and record are real” is only the beginning of a COA review. This particular file reports HPLC purity, HPLC-based identity confirmation and quantity. It does not include LC-MS identity, endotoxin, sterility or heavy-metal results. A working verification portal cannot supply tests that were never performed or reported.

This review did not start with a search for a new laboratory to critique. We were examining a peptide vendor, opened the first COA we found, and saw a laboratory name we had not encountered often: Accumark Labs.

That is exactly when a PDF should become the start of a due-diligence trail—not the end of one. We checked whether the laboratory had a functioning website, whether the report resolved through an independent lookup, whether the public service descriptions matched the tests shown, and whether the certificate supported the vendor's broader claims.

The file examined here is Omni Peptides BPC-157 10 mg, AccuVerify code KF4C-7SJ7. This is a review of one public record and Accumark's current public materials, not an audit of every report the lab has issued.

Accumark identifies itself as an Anaheim, California laboratory and a DBA of Valence Analytical LLC. Its site publishes a street address and phone number, describes its AccuVerify record system, and lists ISO/IEC 17025 accreditation as pending.

The public footprint is newer and smaller than those of long-established reference laboratories. That is not evidence that the lab is illegitimate. It does mean buyers have less historical data available for judging consistency across time, compounds, methods and analysts.

The laboratory's pitch centers on a $250 core peptide panel, 48–72 hour standard turnaround, downloadable certificates and a unique verification URL. Those are useful operational features. They should still be evaluated separately from analytical scope.

Accumark's current service page describes its core panel as HPLC identity confirmation, HPLC purity and quantity verification. Endotoxin testing by LAL and sterility testing by PCR are sold as add-ons. Those safety-related tests are distinct from the $250 core panel.

The same page lists LC-MS identity, NMR, residual-solvent testing and residual-moisture testing in its development roadmap. Most importantly for this certificate, LC-MS identity is listed for a later launch than the July 20 report date. The July record therefore should be read as HPLC-based identity evidence, not mass-spectrometric confirmation.

Yes. AccuVerify code KF4C-7SJ7 resolves to an “Authenticity Confirmed” record for OMNI Peptides. The portal says the result was generated by Accumark Labs and rendered from its LIMS. Its client, compound, lot, dates and analytical values match the public certificate.

The record identifies BPC-157, lot PT-850c8bdac31e-9, received July 16, 2026 and completed July 20, 2026. It reports 99.896% purity against a specification above 98%, an identity result of BPC-157 marked conforming, and measured quantity of 11.72 mg.

A live laboratory record is meaningfully better than an unverifiable PDF. It makes casual document alteration harder and lets readers compare the vendor copy with data shown by the issuing laboratory. It does not independently prove how the sample was selected, who handled it before receipt, or whether the vial came from inventory offered to customers.

Accumark describes its current core identity service as HPLC identity confirmation. A retention-time comparison under a defined method can support that a sample's principal peak behaves like a reference material on that chromatographic system.

That evidence is not equivalent to LC-MS confirmation. Mass spectrometry adds molecular-mass information, while more advanced methods may be needed to characterize sequence, related substances or structural variants. The Accumark record supports HPLC-based conformity; it should not be rewritten as proof that mass spectrometry confirmed this July sample.

This distinction matters because Omni's public product material may use broader language about HPLC and mass spectrometry. Readers should evaluate the tests shown on the batch-specific laboratory record, not a general testing statement elsewhere on a vendor site.

The Omni record does not report endotoxin, sterility or heavy metals. It also does not show an LC-MS result. None of those omissions makes the reported HPLC purity value false; they mean the certificate cannot answer those separate questions.

HPLC area purity answers a chromatographic question. It is not a substitute for biosafety testing and does not establish that a reconstituted research vial is sterile or suitable for human use. Our guide to reading a peptide COA explains why identity, purity, quantity and safety tests must be scored as separate evidence categories.

The record reports 11.72 mg for a product labeled 10 mg. That may reflect intentional overfill, but the public certificate does not describe the quantitative assay or calculation basis in enough detail to determine how water, counter-ion or other corrections were handled. The number should be reported as Accumark's measured quantity—not expanded into a more specific method claim.

The portal also displays lot PT-850c8bdac31e-9. We could not independently establish from the public record how Omni maps that identifier to its manufacturing or retail inventory. A buyer comparing the report with a product should confirm that the same lot appears on the vial or packaging.

Verification proves that a laboratory record exists. Chain of custody asks a different question: whether the sample tested is traceably representative of the products offered for sale.

We credit the evidence that is actually present: a reachable laboratory, a live record tied to the named client, high reported HPLC purity and a reported quantity. We do not award absent methods by implication.

That means the portal and HPLC result have value, while the lack of LC-MS and biosafety results limits the scope of this specific certificate. Accumark's pending accreditation status and comparatively short public history also warrant continued observation as more reports become available.

Our full vendor grades consider multiple evidence dimensions and sampling depth; no single COA decides a vendor's entire grade. The public overview of how Peptide Protocols COA grades work explains those categories without turning one favorable chromatogram into a blanket quality claim.

Accumark Labs is not merely a name printed on a PDF. It has a public location and contact information, a disclosed corporate relationship, current service descriptions and a working record-verification system. The Omni BPC-157 certificate resolves to a matching laboratory record.

The evidence should still be described at its actual resolution. This report supports a high-purity HPLC finding, HPLC-based identity conformity and a reported quantity. It does not show LC-MS identity confirmation, endotoxin, sterility or heavy-metal results.

Our present verdict is therefore narrower than either “fake lab” or “reference-grade release panel”: Accumark appears to be a real, reachable laboratory, and this is a verifiable HPLC-focused record with important analytical gaps. Future LC-MS availability, accreditation, method transparency and a larger body of public reports may strengthen—or complicate—that assessment.

For compound context, see the BPC-157 research guide. To compare how laboratory evidence is reflected at the vendor level, browse the peptide vendor reviews.